▲ Peaking
Business
Kyverna ‘resetting conversation’ with 1-year miv-cel data as autoimmune CAR-T peers hit safety snags
Kyverna's miv-cel data resets conversation in autoimmune CAR-T therapy.
Car-T
7 independently detected trends connected to this subject, with the latest coverage first.
What Archynetys tracks about Car-T
This hub groups 7 separate news trends connected to Car-T, spanning August 18, 2026 through September 25, 2026. Each event page combines source coverage, attention velocity and a time-stamped explanation instead of treating every headline as a separate story.
The record below represents 58 article observations and 58 source signals, led by Business, Health coverage. Use it to compare how individual events emerged, spread and changed over time.
◼ Archived
Health
🔮 fades ✓
A 3-Year-Old's Metastatic Cancer Disappeared After Two Doses of Experimental Therapy
14 news sources are covering this Health story right now — Archynetys is tracking how fast it spreads.
◼ Archived
Business
🔮 fades ✓
Bristol Myers' blood cancer cell therapy succeeds in mid-stage trial
Bristol Myers' blood cancer cell therapy achieves key milestone in mid-stage trial
◼ Archived
Business
🔮 fades ✓
Personalized mRNA cancer vaccines offer new hope. We explain
Personalized mRNA cancer vaccines spark a biotech gold rush, drawing investors and reshaping oncology treatment.
◼ Archived
Business
🔮 fades ✓
Novartis, Bristol Myers pause autoimmune CAR-T trials due to safety concerns
Novartis and Bristol Myers have halted autoimmune CAR-T trials after three patient deaths.
◼ Archived
Health
🔮 fades ✓
Cell therapy substantially reduces severe rheumatoid arthritis in first clinical trial
A cancer therapy has shown promise in treating severe rheumatoid arthritis, offering new hope to patients.
◼ Archived
Business
Exclusive: Third death in China's popular but opaque trials revealed, this time in CAR-T
A third death in China's gene therapy trials raises questions about the safety and oversight of these experimental treatments.